CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience

Expert Review of Clinical Immunology
Kristine A FrerichsNiels W C J van de Donk

Abstract

Multiple myeloma (MM) is generally an incurable hematological malignancy with heterogeneous overall survival rates ranging from a few months to more than 10 years. Survival is especially poor for patients who developed disease that is refractory to immunomodulatory drugs and proteasome inhibitors. Areas covered: This review will discuss the importance of CD38-targeting antibodies for the treatment of MM patients to improve their outcome. Expert commentary: Intense immuno-oncological laboratory research has resulted in the development of functionally active monoclonal antibodies against cell surface markers present on MM cells. In this respect, CD38-targeting antibodies such as daratumumab, MOR202, and isatuximab, have high single agent activity in heavily pretreated MM patients by virtue of their pleiotropic mechanisms of action including Fc-dependent effector mechanisms and immunomodulatory activities. Importantly, CD38-targeting antibodies are well tolerated, with infusion reactions as most frequent adverse event. Altogether, this makes them attractive combination partners with other anti-MM agents. Daratumumab is already approved as monotherapy and in combination with lenalidomide-dexamethasone as well as bortezomib-dexameth...Continue Reading

References

Jan 4, 2001·Leukemia Research·S DeaglioF Malavasi
Aug 17, 2004·The Journal of Allergy and Clinical Immunology·Michael I KotlikoffPrescott G Woodruff
Aug 2, 2005·Cancer Treatment Reviews·Eva Kimby
Dec 8, 2007·Nature Reviews. Immunology·Falk Nimmerjahn, Jeffrey V Ravetch
Jun 6, 2008·Leukemia·M A DimopoulosH Ludwig
Dec 5, 2008·Molecular Medicine·Alberto L HorensteinFabio Malavasi
Sep 25, 2010·Cancer Treatment Reviews·Niels W C J van de DonkAntonio Palumbo
Oct 14, 2010·Clinical Chemistry·Christopher R McCuddenMonte S Willis
Dec 29, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michel de WeersPaul W H I Parren
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
Jul 19, 2011·Blood·Fabio MalavasiNicholas Chiorazzi
Aug 20, 2011·Leukemia·N W C J van de DonkH M Lokhorst
May 25, 2012·The New England Journal of Medicine·David G Maloney
Jun 1, 2013·Expert Opinion on Pharmacotherapy·Niels W C J van de Donk, Henk M Lokhorst
May 27, 2014·American Society of Clinical Oncology Educational Book·P Leif Bergsagel
Jul 6, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jutta DeckertVéronique Blanc
Jul 23, 2014·Annals of the New York Academy of Sciences·Valeria QuaronaFabio Malavasi
Sep 13, 2014·Hematology/oncology Clinics of North America·Niels W C J van de Donk, Pieter Sonneveld
Oct 10, 2014·Blood·Irene M Ghobrial, Ola Landgren
Nov 16, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Inger S NijhofTuna Mutis
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Mar 13, 2015·Transfusion·Claudia I ChapuyRichard M Kaufman
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Aug 27, 2015·The New England Journal of Medicine·Henk M LokhorstPaul G Richardson
Feb 13, 2016·Immunological Reviews·Niels W C J van de DonkPaul W H I Parren
Mar 31, 2016·Clinical Chemistry and Laboratory Medicine : CCLM·Christopher McCuddenA Kate Sasser
Apr 28, 2016·The New England Journal of Medicine·Philippe MoreauUNKNOWN TOURMALINE-MM1 Study Group
May 11, 2016·International Journal of Laboratory Hematology·N W C J van de DonkS Zweegman

❮ Previous
Next ❯

Citations

Feb 28, 2020·Expert Review of Clinical Immunology·Caroline Diorio, David T Teachey
Jan 16, 2020·Cells·Ilaria SaltarellaMaria Antonia Frassanito
Dec 22, 2020·Terapevticheskiĭ arkhiv·I N Bobkova, E S Kamyshova
Mar 18, 2021·Journal of Oncology·Sanyog DwivediLuis F Montaño
Aug 30, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ondřej LidickýTomáš Etrych

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

© 2022 Meta ULC. All rights reserved